MedTrace Logo

Meropenem Dosage Strategy Based on PPK Model

NCT01944319 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2016-02-25

Study results available
· View outcomes & findings →

Summary

To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.

Conditions

  • Lower Respiratory Tract Infection

Interventions

DRUG

Routine meropenem therapy

Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician

DRUG

Meropenem therapy based on a PPK and PD model

Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model

Sponsors & Collaborators

  • Qingtao Zhou

    lead OTHER

Principal Investigators

  • Qingtao Zhou, M.D. · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944319 on ClinicalTrials.gov